Vectorious Medical Technologies

Company Overview

Snapshot

Founded in October 2011 by Eyal Orion, Vectorious Medical Technologies operates with 51–200 employees. The company raised $19.5M across 4 funding rounds from 11 investors. In September 2025, Vectorious Medical Technologies was acquired by Edwards Lifesciences.

Business overview

Vectorious Medical Technologies develops an in-heart microcomputer designed to monitor the left atrial pressure in heart disease patients. Its core product, the V-LAP sensory implant, is a digital, wireless, battery-less device that communicates from within the body, providing high-resolution waveform morphology for actionable feedback. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Digital Healthcare, serving markets that include patients and healthcare providers with solutions for remote monitoring and diagnostics.

Strategic signal

This exit provides a clear signal to investors about the commercial viability and strategic importance of innovative implantable monitoring solutions within the cardiology and medical device sectors, highlighting a trend towards integrating advanced diagnostics for improved patient outcomes.

Company Intelligence Q&A

What was a significant corporate milestone for Vectorious Medical Technologies?

Vectorious Medical Technologies was acquired by Edwards Lifesciences in September 2025.

When did Vectorious Medical Technologies receive a breakthrough device designation?

In November 2020, Vectorious Medical Technologies was granted a breakthrough device designation for its left atrial pressure monitoring device.

What was the outcome of the VECTOR-HF I study?

In May 2022, Vectorious Medical Technologies announced that the VECTOR-HF I study confirmed the safety and accuracy of its V-LAP In-Heart Sensor for left atrial pressure management of heart failure.

When did Vectorious Medical Technologies begin the VECTOR-HF II study?

In February 2022, Vectorious Medical Technologies began the VECTOR-HF II study for its implantable in-heart sensor, focusing on left atrial pressure-guided patient self-management of heart failure.

Which investors participated in the July 2018 funding round?

In July 2018, Fresenius Medical Care Ventures led a funding round for Vectorious Medical Technologies.